In Vitro Diagnostics (IVD) Market Size to Soar Past US$ 25 Billion by 2024

In vitro diagnostics are diagnostic devices and equipment that extract vital information about an individual or patient after a sequence of tests. Introduction of novel diagnostics test applications on the backdrop of advancements and innovations in the IVD technologies by various organizations has resulted in rampant growth of the in vitro diagnostics (IVD) market, which is expected to sustain in the near future. Diagnoses and tests are precursors to any treatment, which makes in vitro diagnostic market highly lucrative. However, majority of the tests are remotely performed making their presence and use unnoticed. Furthermore, increasing elderly population base and rising demand for diagnostic testing is projected to spur growth of the in vitro diagnostics (IVD) market over the forecast period (2016–2024). Also, growing prevalence of diabetes has increased the demand for in vitro diagnostic tests in the recent past, which is further expected to add on to the sales revenue of the in vitro diagnostic market. In 2014, as per National Diabetes Statistics Report 2014, around 9.3% of the population in the U.S. suffered from diabetes and around 28.0% were undiagnosed.

Rapid strides made in technology and inclination of healthcare providers towards expanding their product portfolio is fueling growth of this highly lucrative market, especially in emerging economies, which are largely untapped. Furthermore, rise in prevalence of infectious disease globally, especially in Asia Pacific would inadvertently support market growth in the near future. Major organizations in the in vitro diagnostic market are actively focusing on introducing novel technologies in the testing and diagnostic segments of molecular biology. Such initiatives are projected to bring about a rapid shift in the dynamics of in vitro diagnostics (IVD) market, with Asia Pacific taking on the mantle from North America to emerge as the largest market for in vitro diagnostics, owing to latest technologies and uninterrupted investment in the health care sector is expected further to support the growth in in vitro diagnostic market in the near future.

Request a sample copy of this report: http://bit.ly/2wO4bV1

Infectious diseases has emerged as the highest revenue contributor among application segment

Infectious diseases has emerged as the highest revenue generating application for In vitro diagnostics (IVD) market industry players. The segment is expected to grow by 1.5X at a CAGR of 4.4% between 2016 and 2024. Infectious diseases prevalence has increased considerably in past. Morbidity cases in tuberculosis, salmonella and meningococcal disease was as high as 90,000 in U.S. in 2016. As a result, the demand for IVD from diagnostic centers has increased substantially. As per the Centers for Disease Control and Prevention (CDC), over 3.9 million patients visited hospital outpatient department for infectious and parasitic diseases. Demand for IVD is expected to register fastest growth in detection of autoimmune disorders and infectious diseases.

North America is expected to dominate the market revenue throughout the forecast period

North America is highest contributing region for In vitro diagnostics (IVD) market, with a projected market share of 46.7% by 2024, expanding at the fastest CAGR of 5.4% between 2016 and 2024. Changing healthcare landscape, favorable regulatory policies such as Medicaid and Medicare along with significant healthcare spending (16.7%) is expected to boost the market for IVD in the region. Though the market outlook seems lucrative in North America, reimbursement pressure, increased usage of companion diagnostic and significant growth potential of next generation sequencing (NGS) are key challenges for the industry players in the North America. Companion diagnostics market is proliferating at faster market pace compared to IVD. As such, product innovation in the segment is the key focus area for market players. North America has also seen some of the major mergers and acquisitions in the recent past, to tap into market opportunities. For instance, Roche acquired Ventana Medical in 2008. In 2011, Novartis acquired Genoptix to capture a greater chunk of market in the U.S.

Click here to know more about this publish report: http://bit.ly/2yclhwY

Market players need to invest in R&D and follow inorganic growth to generate high ROI in longer run

Market players are focused towards research and development to expand their business reach in the market. Moreover, industry players are focused towards generating revenue from respective key product segment. For instance, while Roche and Siemens are active players in clinical chemistry IVD product segment, Allere and Abbott holds key market share in point of care IVD solutions. Furthermore, the In vitro diagnostics (IVD) market is expected to witness mergers and acquisition in near future, wherein leading players are expected to acquire regional companies based in emerging economies. Similar trends have been noticed in recent past where leading players acquired/partnered with regional players. For instance, Roche acquired majority stake in Foundation medicine with US$ 1.2 Bn in 2015.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.